In summary, the data described above strongly suggest that the FGFR pathway is capable of promoting tumor progression even in the presence of CDK4/6 inhibitors and that the addition of FGFR inhibitors is a promising therapeutic avenue to delay or stop tumor progression—in particular, for CDK4/6 inhibitor-resistant BC. The gene discussed is CDK4; the disease is breast cancer.